Skip to content

Optimization of Stem Cell Collection of Related Healthy Donors Based on Peripheral Blood CD34+ Cell Count Thresholds

Optimization of Stem Cell Collection of Related Healthy Donors Based on Peripheral Blood CD34+ Cell Count Thresholds

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600115894
Enrollment
Unknown
Registered
2026-01-04
Start date
2026-01-04
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

D4 Group:Collection of stem cells began on the fourth day of the mobilization process
D5 Group:Collection of stem cells began on the fifth day of the mobilization process

Sponsors

The First Affiliated Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1.Aged 18 to 60, both men and women are eligible; 2.Body weight >= 40 kg; 3.Related donors scheduled for PBSC mobilization and collection; 4.Willing and able to provide informed consent; 5.Willing to abide by the research plan and requirements; 6.On the fourth day of the mobilization, the number of peripheral blood CD34+ cells in the donors was greater than 40 cells/µL. 7.No G-CSF related grade 3 or higher adverse events occurred. 8.Peripheral venous access assessment is qualified (capable of supporting >=3-hour single blood collection);

Exclusion criteria

Exclusion criteria: 1.Pregnant and lactating women; 2.There is severe dysfunction of the heart, liver, kidneys and brain; 3.Allergic to G-CSF; 4.Those with active infectious diseases, autoimmune disorders, severe infections or uncontrolled mental illnesses; 5.Combine with other malignant tumors; 6.Currently participating in other clinical trials; 7.Unable to understand or unable to cooperate in completing the research plan; 8.Other situations that the researchers considered as not suitable for inclusion in the study;

Design outcomes

Primary

MeasureTime frame
Collection success rate;

Secondary

MeasureTime frame
Direct medical costs;The number of CD34+ cells in the collected product;Incidence of adverse reactions;

Countries

China

Contacts

Public ContactYiying Xiong

The First Affiliated Hospital of Chongqing Medical University

xiongyiying@foxmail.com+86 23 8901 1876

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026